Drug Company Files for Orphan Drug Designation for Mesothelioma Treatment

Treatment & Doctors
Reading Time: 3 mins
Publication Date: 10/26/2011
Fact Checked
Our fact-checking process begins with a thorough review of all sources to ensure they are high quality. Then we cross-check the facts with original medical or scientific reports published by those sources, or we validate the facts with reputable news organizations, medical and scientific experts and other health experts. Each page includes all sources for full transparency.

Asbestos.com is the nation’s most trusted mesothelioma resource

The Mesothelioma Center at Asbestos.com has provided patients and their loved ones the most updated and reliable information on mesothelioma and asbestos exposure since 2006.

Our team of Patient Advocates includes a medical doctor, a registered nurse, health services administrators, veterans, VA-accredited Claims Agents, an oncology patient navigator and hospice care expert. Their combined expertise means we help any mesothelioma patient or loved one through every step of their cancer journey.

More than 30 contributors, including mesothelioma doctors, survivors, health care professionals and other experts, have peer-reviewed our website and written unique research-driven articles to ensure you get the highest-quality medical and health information.

About The Mesothelioma Center at Asbestos.com

  • Assisting mesothelioma patients and their loved ones since 2006.
  • Helps more than 50% of mesothelioma patients diagnosed annually in the U.S.
  • A+ rating from the Better Business Bureau.
  • 5-star reviewed mesothelioma and support organization.
Learn More About Us


"My family has only the highest compliment for the assistance and support that we received from The Mesothelioma Center. This is a staff of compassionate and knowledgeable individuals who respect what your family is experiencing and who go the extra mile to make an unfortunate diagnosis less stressful. Information and assistance were provided by The Mesothelioma Center at no cost to our family."
Mesothelioma patient’s daughter
  • Google Review Rating
  • BBB Review Rating

How to Cite Asbestos.com’s Article


Hall, M. (2020, October 16). Drug Company Files for Orphan Drug Designation for Mesothelioma Treatment. Asbestos.com. Retrieved December 3, 2022, from https://www.asbestos.com/news/2011/10/26/drug-company-files-for-orphan-drug-designation-for-mesothelioma-treatment/


Hall, Mark. "Drug Company Files for Orphan Drug Designation for Mesothelioma Treatment." Asbestos.com, 16 Oct 2020, https://www.asbestos.com/news/2011/10/26/drug-company-files-for-orphan-drug-designation-for-mesothelioma-treatment/.


Hall, Mark. "Drug Company Files for Orphan Drug Designation for Mesothelioma Treatment." Asbestos.com. Last modified October 16, 2020. https://www.asbestos.com/news/2011/10/26/drug-company-files-for-orphan-drug-designation-for-mesothelioma-treatment/.

Mesothelioma patients soon may have a new treatment option to consider for their rare and aggressive cancer.

Pinnacle Biologics, Inc., an Illinois-based bio-pharmaceutical company, announced this week it filed an Orphan Drug Designation (ODD) for its product PHOTOFRIN as an aid in the surgical treatment of malignant pleural mesothelioma.

Such a designation, often applied to drugs and treatments of diseases and conditions affecting 200,000 people or less, provides a special status for the drug. It will allow the manufacturer to receive tax credits and marketing incentives.

This program, put in place by The Orphan Drug Act, was designed to ensure that patients of rare diseases like mesothelioma were able to receive hopeful treatments despite the fact that the economic incentives of developing cures or treatments for large markets didn’t exist for rare diseases.

The cancer, primarily caused by asbestos exposure, affects between 2,000 and 3,000 Americans per year and has no known cure. Diseases of such limited populations fit ideally within the orphan drug classification.

A Sense of Hope

Pinnacle’s chairman, Guillermo Herrera, conveyed a positive stance on the company’s recent filing.

“We are pleased to file for the Orphan Drug Designation of PHOTOFRIN and potentially for its utilization in Mesothelioma,” Herrera said. “The treatments are palliative at best, and the outcome in patients with malignant pleural mesothelioma is poor. Pinnacle is committed to support the approval and expand the use of PHOTOFRIN® into new indications, where preliminary clinical results are very encouraging.”

Some medical experts have expressed optimism about the treatment as an option for patients.

“Photodynamic therapy (PDT), in conjunction with surgery, has shown some very promising results for the treatment of mesothelioma, a highly lethal cancer of the chest cavity lining,” said Joseph S. Friedberg, M.D., co-director of the Penn Mesothelioma and Pleural Disease Program at Penn Medicine, which is studying the treatment. “We have been able to develop a technique where we can reliably preserve the patient’s lung. When compared to other treatments, this combination of lung-sparing surgery, PDT and standard chemotherapy appears to have a positive impact on both survival and quality of life. . . . [I]t has become a major focus of our research.”

Additional Treatment Options

PHOTOFRIN isn’t the only treatment hope for patients.

Beyond Pinnacle’s treatment, patients also have a variety of treatments that are designed to improve survival or increase quality of life, depending on the stage of diagnosis and development of the cancer. These treatments include chemotherapy, radiation, surgery and alternative forms of attacking the cancer.

As this disease is known to be aggressive, patients of asbestos cancer may also have the ability to consider using multiple treatment options to better assist their diagnosis.

Medically Reviewed by Top Mesothelioma Doctors
Free Mesothelioma Guide